University of North Dakota

UND Scholarly Commons
Nursing Capstones

Department of Nursing

3-11-2019

The Use of Selenium in the Treatment of Graves’
Hyperthyroidism
Jenna Monshaugen

Follow this and additional works at: https://commons.und.edu/nurs-capstones
Recommended Citation
Monshaugen, Jenna, "The Use of Selenium in the Treatment of Graves’ Hyperthyroidism" (2019). Nursing Capstones. 124.
https://commons.und.edu/nurs-capstones/124

This Independent Study is brought to you for free and open access by the Department of Nursing at UND Scholarly Commons. It has been accepted for
inclusion in Nursing Capstones by an authorized administrator of UND Scholarly Commons. For more information, please contact
zeineb.yousif@library.und.edu.

Running Head: SELENIUM AND GRAVES’ HYPERTHYROIDISM

The Use of Selenium in the Treatment of Graves’ Hyperthyroidism
Jenna Monshaugen
Family Nurse Practitioner Student
University of North Dakota, Grand Forks, North Dakota

1

SELENIUM AND GRAVES’ HYPERTHYROIDISM

2

Permission
The Use of Selenium in the Treatment of Graves’ Hyperthyroidism
Department: Nursing
Degree: Master of Science

In presenting this independent study in partial fulfillment of the requirements for a graduate
degree from the University of North Dakota, I agree that the College of Nursing & Professional
Disciplines of this University shall make it freely available for inspection. I further agree that
permission for extensive copying or electronic access for scholarly purposes may be granted by
the professor who supervised my independent study work or, in her absence, by the chairperson
of the department or the dean of the Graduate School. It is understood that any copying or
publication or other use of this independent study or part thereof for financial gain shall not be
allowed without my written permission. It is also understood that due recognition shall be given
to me and to the University of North Dakota in any scholarly use which may be made of any
material in my independent study.

Jenna Monshaugen
3/11/2019

SELENIUM AND GRAVES’ HYPERTHYROIDISM

3

Abstract
Multiple studies have found an association between subnormal thyroid stimulating hormone
(TSH), elevated free thyroxine (FT4) and/or triiodothyronine (T3) and increased free radicals
and reactive oxygen species (ROS). These findings are related to the development of Graves’
disease. Graves’ disease is an autoimmune disorder that causes hyperthyroidism and a
hypermetabolic state. The use of selenium has been of interest in the treatment of Graves’
hyperthyroidism. Selenium, an antioxidant that is concentrated in the thyroid gland, is essential
for normal thyroid metabolism and function. Selenium is also thought to reduce oxidative stress
and ROS. Studies and trials currently continue on the use of selenium in the treatment of thyroid
disorders, and thus, more information and discoveries are being made to date. This paper will
review literature on the pathophysiology of Graves’ disease, the role of selenium, and the
utilization of selenium in the treatment of Graves’ hyperthyroidism and the associated common
complication of orbitopathy.
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Background
A 65-year-old Caucasian female came to the clinic with a chief complaint of “feeling
tired but cannot sleep.” Upon further investigation, patient reported a recent unexplained weight
loss of 10 pounds, irritability, poor concentration, occasional heart fluttering sensations, and
intermittent hot flashes. Patient’s physical exam was normal besides an enlarged thyroid. Labs
were obtained and patient had a low TSH, high T4, and high T3. The patient was diagnosed with
hyperthyroidism. Treatment was initiation of a beta-blocker and a referral to endocrinology.
Graves’ disease is the main cause of hyperthyroidism among adults. Nearly 3% of
women and 0.5% of men suffer from Graves’ hyperthyroidism (Wang et al., 2016). In Graves’
disease, autoantibodies are activated against the TSH receptor, which leads to excessive thyroid
hormone production. Genetic and environmental factors have been implicated in the disease
process, as well as, an inflammatory response with an increased production of reactive oxygen
species (ROS) and free radicals that sustain and perpetuate Graves’ disease (Duntas, 2012).
Additionally, thyroid-associated orbitopathy, an inflammatory disorder of the orbit, is the most
common extra-thyroid complication of Graves’ disease, with up to 50% of patients with
hyperthyroidism developing orbitopathy. Oxidative stress and an increase in ROS are a major
cause of orbitopathy in Graves’ disease, which can result in corneal breakdown and loss of vision
(Strianese, 2017).
Currently, treatment for Graves’ hyperthyroidism may include the use of antithyroid
medication, radioactive iodine, surgery, or a combination of these treatments, however none of
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these treatment methods specifically target the underlying autoimmune process of Graves’
disease. In the treatment of Graves’ disease. the antithyroid medications used are
propylthiouracil (PTU) and methimazole (MMI) (Dunphy, Winland-Brown, Porter, & Thomas,
2015). Selenium, a trace element that is an antioxidant, is currently being studied as a possible
treatment for Graves’ hyperthyroidism. An antioxidant decreases oxidative stress and free radical
damage, thereby lessening the autoimmune response. According to Wang et al. (2016) “selenium
is intensively involved in the immune response, and it also has important roles in maintaining the
normal function of the thyroid” (p. 559). Selenium is essential for healthy thyroid gland function,
hormone metabolism, and the degradation of ROS in the thyroid gland. Selenium also interferes
with the inflammatory response that causes thyroid eye disease and is recommended for
treatment in mild orbitopathy (Strianese, 2017). Due to selenium’s role in the inflammatory and
autoimmune response, the use of selenium as an important antioxidant to reduce the ROS
damage in Graves’ hyperthyroidism leading to an euthyroid state may be implicated in practice.
Selenium, which can be bought over the counter as a supplement or ingested in foods, may have
a role in the treatment of Graves’ disease.
Case Report
D.M, 65-year-old Caucasian female
Chief Complaint: Patient reports to clinic with complaint that for the past 6 weeks she “can’t
sleep but feels tired during the day.”
HPI: Patient said she has no trouble falling asleep, but after about 2-3 hours she awakens and is
unable to fall back asleep, as it feels she can’t “unwind” and her “body feels restless”. Patient
denied taking naps during the day, limits herself to 1 cup of coffee in the morning, is not falling
asleep easily throughout the day, and her husband has not complained of her snoring at night.
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Patient also has a recent, unexplained weight loss of 10 pounds. Additionally, patient had
complaints of irritability and poor concentration, but denied forgetfulness. Patient stated
concerns of “heart flutters” that occur during the day or night. She said the flutters last for about
5 minutes and will happen 2-3 times per week. Patient denied dizziness, diaphoresis, changes in
vision, chest pain, jaw pain, shoulder/arm pain, nausea, headaches, or any other symptoms
during her heart flutters. Patient denied a cardiac history. Patient will sit down and rest when
heart flutters occur until they stop. Patient denied a pattern or any known exacerbating features,
such as exercise, to her heart flutters. Patient said she has a history of “vertigo”, but her
symptoms are well controlled, and she can’t even remember when she took her as needed
medication. Patient also was concerned about intermittent hot flashes. Patient stated the hot
flashes occur during the day, about 2 times per week, and will last “a couple minutes.” Patient
denied any of the prior accompanying symptoms or any other symptoms with her hot flashes.
Patient said she is post-menopausal and went through menopause 12 years ago. Patient cannot
recall any pattern to hot flashes or precipitating or exacerbating factors. Patient denied any recent
medicine changes or supplement use. Patient has tried exercise, meditation, limiting caffeine,
lavender lotion, dark room, shutting her door, distraction, and changing rooms to help alleviate
her symptoms. Patient stated nothing has worked and that is why she is in the office today.
Past Medical History: benign positional vertigo, childbirth X2
Surgical History: none
Medications: Antivert PRN, multivitamin daily, calcium daily
Immunizations: up to date
Allergies: None
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Family History: Mother: cardiac stent, Alzheimer’s disease, Father: diabetes mellitus (unknown
if type 1 or 2), Brother: prostate cancer, Brother: healthy, Brother: healthy, Sister: hypertension
Social History: Patient lives at home with husband. Patient has 2 adult children. Patient does not
drink alcohol besides an “occasional 1 glass of wine”, does not smoke, and does not use illicit
drugs. Patient is retired but does volunteer work. Patient exercises 3 times per week.
Review of systems per chief complaint and history of present illness.
Objective:
Weight: 136 pounds, pulse: 96, respirations: 12, temperature: 99.4, BP: 124/74
Physical Exam:
65-year-old Caucasian female, alert, oriented, in no acute distress, well developed. Answers
questions appropriately and able to provide a history. Exam was negative besides an enlarged
thyroid palpated.
Plan:
Completed testing: CBC, CMP, TSH, T4, T3, EKG, UA.
All labs and EKG normal besides TSH was low and T3/T4 elevated. Patient started on a betablocker for heart rate control, heart flutter symptom control, and to possibly lessen restlessness
and sleeplessness. A referral for endocrinology was placed for further management. Explained to
patient the thyroid gland, its function, and the diagnosis of hyperthyroidism. Informed patient of
different treatment options for hyperthyroidism and stated that endocrinology will further explain
and help patient make the best decision for her. All patient’s questions answered. Patient to
follow-up in 6 weeks or per endocrinology recommendations.
Literature Review

SELENIUM AND GRAVES’ HYPERTHYROIDISM

8

A literature search was conducted through CINAHL, PubMed, textbooks, and
GoogleScholar. The phrases “Graves’ hyperthyroidism and selenium”, “hyperthyroidism and
selenium”, “selenium and antithyroid medication”, “selenium treatment in hyperthyroidism”,
“selenium and thyroid” and “Graves’ disease and selenium” were used to generate articles.
Articles were chosen between the years of 2012 and 2019.
Hyperthyroidism is a common condition that includes the excessive production and
excretion of one or both of the thyroid hormones: thyroxine (T4) and triiodothyronine (T3).
Graves’ disease, an autoimmune disorder, is the most common cause of hyperthyroidism in the
United States, accounting for 80-90% of all hyperthyroid cases (Dunphy et al., 2015). About 3%
of women and 0.5% of men have Graves’ hyperthyroidism. In Graves’ disease, it is known that
anti-TSH-receptor antibodies (TRAb) bind to TSH receptors. This binding of receptors causes
thyroid hypertrophy and stimulates the production of thyroid hormones (Wang et al., 2016). The
stimulation of thyroid hormone production leads to the increased T3 and T4, and the binding of
receptors causing thyroid hypertrophy is consistent with the enlarged thyroid that may be
palpated on exam, both findings commonly identified in Graves’ disease. Anti-TSH-receptor
antibodies are often used as an antibody marker for this disease.
Graves’ hyperthyroidism is known to have genetic and environmental factors that trigger
the autoimmune process in the disease. At a cellular and genetic level, a human leukocyte
antigen (HLA), a gene complex that is responsible for regulating the immune system, develops a
defect in suppressor T-lymphocyte function. This defect leads to decreased suppression of
thyroid-directed T-lymphocytes. The subsequent proliferation of helper T-lymphocytes, as a
result of decreasing suppressor T-lymphocytes, produces interferon and interleukin-1, which are
cytokines that differentiate B cells to plasma cells and ultimately generate TRAb (Duntas, 2012).
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According to Duntas (2012) interferon “modulates the autoimmune process and, by stimulating
chemokine production by thyroid follicular cells, contributes to the maintenance of the
autoimmune process” (p. 2). Thus, through genetic mutations on the HLA gene, suppressor Tlymphocytes are decreased allowing for the proliferation of helper T-lymphocytes. Helper Tlymphocytes, interferon, and interleukin-1 all work in conjunction that differentiate B cells to
plasma cells and generate TRAb. As stated earlier, TRAb is an autoantibody that binds to TSH
receptors and stimulates the production of T3 and T4, leading to hyperthyroidism. This increased
thyroid hormone production may further reduce the number and function of suppressor Tlymphocytes and stimulate helper T-lymphocytes, which will perpetuate the cycle. Other factors
known to contribute to Graves’ hyperthyroidism are stress, age, smoking, and female gender
(Calissendorff, Mikulski, Larsen, & Moller, 2015). It is also common for persons with Graves’
disease to also have concurrent autoimmune disorders such as vitiligo, type I diabetes mellitus,
or adrenal insufficiency (Dunphy et al., 2015).
Oxidative stress, through the release of free radicals and ROS, is thought to play a large
role in the development of hyperthyroidism. When a patient suffers from hyperthyroidism, an
increase of thyroid hormones causes the patient to be in a hypermetabolic state. This
hypermetabolic state forms and releases a large amount of ROS in the peripheral tissues and the
thyroid gland. Even the normal production of thyroid hormones causes ROS damage to the
thyroid gland; thus, when the production is increased, as in the case of Graves’ hyperthyroidism,
even more thyroid hormone is produced, causing an increase in oxidative stress on the thyroid
gland. It is believed that ROS elicits damage to the thyroid epithelial cells, resulting in exposure
of autoantigens to the immune system, causing worsening of autoimmunity against the thyroid
gland. The ROS that are generated in the peripheral tissues cause damage to those tissues,
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contributing to various clinical manifestations of Graves’ hyperthyroidism, including
orbitopathy, anxiety, fine hand tremors, heat sensitivity, and weight loss (Marino, Menconi,
Dottore, Leo, & Marcocci, 2018). Two major elements in the oxidative stress associated with
Graves’ hyperthyroidism are H2O2 and superoxide anion (O2-). Hyperthyroidism not only
increases H2O2 , O2-, and oxidative stress, which contributes to tissue damage and continues the
cycle of ongoing damage, but also decreases antioxidants, which leads to further oxidative stress.
(Duntas, 2012). Because of this knowledge, an area of interest in treating Graves’
hyperthyroidism is through the use of antioxidants. A goal of antioxidant therapy would be to
reduce H2O2 to H2O, and O2- to O2, resulting in limiting the damage to the thyroid gland and
peripheral tissue.
Selenium, a trace mineral, is important in thyroid health. The thyroid gland is
characterized by a high tissue concentration of selenium. Selenium contributes to antioxidant
defense in the thyroid by removing ROS generated during the production of thyroid hormones
(Ventura, Melo, & Carrilho, 2017). It is a nonmetal mineral, trace element, and an essential
micronutrient. In recent years there has been a growing interest in selenium, as it has been shown
to be crucial in the role of maintenance of immune-endocrine function, metabolism, and cellular
homeostasis. The selenoproteins, proteins made up of selenium, have important roles in
antioxidant activity, contributes to the defense against oxidative stress, and removes the oxygen
free radicals generated through the production of thyroid hormones (Ventura et al., 2017).
Selenium is incorporated into selenoproteins as the 21st amino-acid, selenocysteine. The
Selenoproteins have a wide range of important effects that include redox homeostasis, immunity,
and the reproduction and metabolism of thyroid hormones. Selenoproteins important in thyroid
function are glutathione peroxidase and thioredoxin reductases (Winther et al., 2014).
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The selenoproteins glutathione peroxidases and thioredoxin reductase have a critical role
in a complex defense mechanism that maintains normal thyroid function by protection the gland
from H2O2 and ROS. They are shown to have of benefit in autoimmune thyroid disease by
slowing down the autoimmune process (Watt et al., 2013). Since Graves’ disease is an
autoimmune process that involves free radical and ROS damage, the damage further perpetuates
thyroid dysfunction and continues the disease process and hyperthyroid state. Since selenium is
known to blunt the autoimmune process and is heavily saturated in the thyroid gland, this trace
mineral is researched as a treatment option for Graves’ hyperthyroidism (Leo et al., 2016) This is
meaningful because the current conventional treatments of anti-thyroid medications, radioactive
iodine, and surgery only treat the thyroid gland but not the autoimmune process. In addition to
the autoimmune protection of decreasing oxidative stress, selenium supplementation has shown
to decrease helper T-lymphocytes and upregulate suppressor T-lymphocytes, which puts a brake
on the immune response. Through this mechanism with selenium, T-lymphocyte levels may be
normalized. There is also a correlated increase in glutathione peroxidase levels with selenium
intake, which has a protective role in the defense mechanism (Kahaly, Riedl, Konig, Diana,
Schomburg, 2017).
To further explain the selenoproteins, glutathione peroxidase has an enzymatic function,
in which selenium is located on the catalytic site. This is important in the antioxidant action of
the enzyme, as catabolism breaks down a substance. Glutathione peroxidase protects the thyroid
gland from oxidative stress by reducing H2O2 into H2O (Leo et al., 2017). Thioredoxin reductase
is induced by stress. It has strong redox activities, thus decreasing oxidative stress. Thioredoxin
reductase has also been implicated in the regulation of the production T3 in Graves’ disease
(Duntas, 2012). Furthermore, glutathione peroxidase is found in other tissues, which helps
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explain the extra-thyroid clinical manifestations that occur with Graves’ hyperthyroidism. All of
the glutathione peroxidases have an antioxidant defense and protects the tissues where it is
concentrated. Thioredoxin reductase has a cytosolic function that acts as a main antioxidant at
the cellular level and a mitochondrial function that regulates cell proliferation. Lastly, there is
another selenoprotein, iodothyronine deiodinase that is active in the conversion of T4 to reverse
T3, which is the inactive metabolite (Ventura et al., 2017). These are the main groups of
selenoproteins that are found in the thyroid gland and are important in the normal function of the
thyroid gland.
Selenium is available in organic compounds known as selenomethionine and
selenocysteine, or in inorganic compounds known as selenite and selenate. The organic form is
known to have better absorption and is the preferable formula for supplementation and treatment.
Selenomethionine is found in vegetables sources (Ventura et al., 2017). Supplements containing
selenomethionine have the highest bioavailability of selenium. The amount of selenium a person
consumes varies by region and is also dependent on the soil and water concentration in that area.
It is commonly found in animal food sources such as fish, ham, beef, cottage cheese, and eggs.
Other food sources of selenium are pasta, rice, bread, and cereal. Reduced selenium levels have
also been found in smokers, elderly, large consumption of white rice, alcohol use, and
consumption of coffee (Ventura et al., 2017). The daily recommended intake of selenium is 53
micrograms in women and 60 micrograms in men. Since selenium is found in a wide variety of
foods, diet restrictions or preferences do not largely impact the consumption of selenium. The
variance of selenium concentration in the environment plays a larger role in plasma selenium
levels, which can influence if a person will suffer from a selenium deficiency and subsequent
disease states. If the environment is known to be deficient in selenium, a person may have to take
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a prepared selenium supplement to assist in controlling the autoimmune process and oxidative
stress in Graves’ disease; otherwise, it is best if a person obtains selenium through diet.
Due to antioxidant properties, selenium has been used as part of the treatment for Graves’
hyperthyroidism and hyperthyroidism orbitopathy. The use of the mineral is controversial, and
more research is being conducted to support or discredit selenium in the treatment of
hyperthyroidism. In a study performed by Zheng et al., (2018) there was a decrease in free T3
levels in patients taking the anti-thyroid medication methimazole (MMI) and selenium. A
decrease in free T3 and a difference between the selenium and control group was noted in the
three-month group, but not at the nine-month mark. There was also a decrease, higher in the
patients taking MMI and selenium versus patients just taking MMI, in the free T4 levels at three
months and six months, but not at nine months. Selenium supplementation with MMI showed a
higher TSH level at six months but did not display an increase at three months or nine months.
Lastly, TRAb levels were also evaluated in these patients. Patients taking MMI with selenium
had a decrease of TRAb levels at six months but not at nine months (Zheng et al., 2018). It is
interesting to note that the patients did have measurable benefits while taking MMI with
selenium. The patients had a significantly faster decrease in free T3, T4, and TRAb, while
having an increase in TSH. This study showed that patients reached a euthyroid state faster when
utilizing selenium with MMI than just with MMI. Additionally, the use of only anti-thyroid
medication is associated with a high rate of recurrence. Wang et al. (2016) noted that “about 50%
patients will achieve remission after receiving ATDs [anti-thyroid drugs] therapy for about 12-18
months, but there is a high prevalence of recurrence in those patients with remission, ranging
from 30 to 70% in published studies” (p. 559). Thus, the use of selenium was of particular
interest in treating Graves’ hyperthyroidism and recurrent hyperthyroidism, since a second round
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of anti-thyroid medication is less likely to induce and maintain an euthyroid state, and the only
other treatment methods are radioactive iodine and surgery. In patients with recurrent Graves’
hyperthyroidism, selenium was added to MMI therapy to possibly enhance the effectiveness of
the MMI and induce euthyroid. In the group treated with selenium and MMI, the concentration
of free T4, free T3, and TRAb decreased faster than those treated with just MMI at the twomonth follow-up, with higher TSH levels noted at the two month follow up, as well (Wang et al.,
2016).
In recurrent Graves’ hyperthyroidism, 52.3%, were able to attain and maintain a
euthyroid state when taking selenium with MMI. Only 25% of patients taking only MMI were
able to attain remission. Overall, higher remission rates in Graves’ hyperthyroidism are
associated with selenium use, as well as, a faster response to anti-thyroid medication (Wang et
al., 2016).
Reaching a euthyroid state is often noted to be quicker in patients receiving selenium
with MMI than patients taking only MMI. In further support of this role of antioxidant use, the
TRAb levels correlated with the levels of free T3, free T4, and TSH. Early on in the studies
TRAb levels dropped quicker with the use of selenium when compared to those without
selenium use. As the TRAb levels dropped, the free T3 and T4 levels dropped and the TSH
levels increased. These findings support the positive impact combining selenium and MMI may
have in autoimmunity and faster control and normalization of the thyroid gland (Ventura et al.,
2017). Additionally, the patients taking selenium therapy consistently had lower levels of free
T3, T4 and TRAb, and higher level of TSH at each of the follow-ups: two months, three months,
six months, and 12 months. (Wang et al., 2016). This evidence is continually backed by other
studies including ones performed by Zheng et al. (2018), Wang et al. (2016), Calissendorff et al.
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(2015), and Ventura et al. (2017). Calissendorff et al. (2015) concluded that after an addition of
selenium to MMI therapy there was a reduction in free T4 and increase in TSH at 18 and 36
weeks. Calissendorff et al. (2015) stated “Se [selenium] is important for initiating and enhancing
immunity but is also involved in regulating excessive immune responses, which is crucial for
preventing responses that may lead to autoimmunity or chronic inflammation” (p. 97).
Patients taking selenium have been able to take a lower dose of an MMI and were less
likely to discontinue the medication than the patients taking only an MMI (Wang et al., 2016). A
larger difference in TSH was noted when patients in the selenium group were increased from 60
micrograms daily to 90 micrograms daily, suggesting that higher doses of selenium may
correspond with a greater TSH response (Calissendorff et al., 2015). Higher remission rates of
Graves’ hyperthyroidism were noted in patients receiving 200 micrograms/day and MMI than
patients receiving 166 micrograms/day and MMI. There was also a larger decrease in TRAb
levels in the patients with 200 micrograms daily versus 166 micrograms daily (Winther,
Bonnema, and Hegedus, 2017). The patient’s initial selenium status may play a role in the dosing
of selenium. Patients may be more prone to selenium deficiency in areas where there is less
selenium in the environment and foods. Knowing that certain regions that have less selenium in
the environment, a higher dose of selenium supplementation may be warranted. Most persons
upper tolerable level of selenium intake is 400 micrograms/day but it is tolerated in short-term
doses up to 10,000 micrograms/day. An excessive amount of selenium can lead to
gastrointestinal discomfort, hair and nail formations or loss, peripheral neuropathy, fatigue,
dizziness, and even more rarely cardiovascular collapse and respiratory distress (Watt et al.,
2013).
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Not all studies cite a clinical benefit of response on TSH in those who concurrently use
selenium supplementation as part of their treatment, but the initial selenium status of the patient
may be a major reason why no benefit was seen. In a study of 70 patients by Kahaly et al.
(2017), no significant changes in free T3, T4, TRAb, and TSH were noted between selenium and
control groups. The relapse rate was also the same between the two groups. A positive
correlation was noted between selenium status and SELENOP (the protein that carries selenium
throughout the body) and TSH. It was hypothesized that the lack of response may have been
related to unknown initial selenium levels of the patients, as well as, small study size and short
study duration (Kahaly et al., 2017). The fact that there was a positive relation between selenium
levels and TSH is promising, as it demonstrates that selenium does have an effect on TSH.
Kahaly et al. (2017) further explains “these divergent results indicate that a direct comparison of
the currently available Se supplementation studies in GD [Graves’ disease] is hampered by the
differences in Se compound, dosage, and time of supplementation chosen, by the baseline Se
status of the patient, which is not always determined…” (p. 4339). In a study where selenium
status was established, all patients were within normal plasma selenium range. When thyroid
hormones and TSH were compared between the 2 groups, there was no difference in the speed of
remission or thyroid levels (Leo et al., 2016). The use of selenium has shown to be of benefit to
patients that are selenium deficient, though; and, since organic selenium is known for better
absorption within the body, the type of supplementation may also play a role in treating Graves’
disease (Ventura et al., 2017).
Selenium supplementation has also shown to decrease the clinical manifestations
associated with hyperthyroidism. Patients taking selenium reported a lower degree of depression.
Furthermore, there was also a positive correlation in recovery from the symptoms of
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hyperthyroidism and selenium use (Calissendorff et al., 2015). There are studies underway,
particularly one that should be published soon by Winther et al. (2014), looking at the quality of
life and treatment with selenium in thyroid disease. The primary outcome of this study is a
patient’s reported quality of life with selenium versus no selenium supplementation, with the
hope that selenium will further support improved quality of life. One of the most studied areas
that pertain to quality of life and Graves’ hyperthyroidism is orbitopathy, since thyroid eye
disease is the most common extra-thyroid problem in Graves’ disease.
Selenium supplementation has been implicated in the treatment of Graves’ orbitopathy, a
common consequence affecting approximately 50% of Graves’ patients (Strianese, 2017).
Oxidative stress and ROS in Graves’ disease are shown to contribute to orbitopathy. This
inflammatory process leads to an increased number of orbital fibroblasts, consequently
increasing the volume of orbital structures and causing the clinical manifestations of Graves’
orbitopathy (Marino et al., 2018). The clinical manifestations of thyroid eye disease include
eyelid retraction, proptosis, ocular motility disturbances, dry eyes, foreign body sensations, and
tearing (Strianese, 2017). Through oxidative stress and ROS damage the etiology of the Graves’
hyperthyroidism and Graves’ orbitopathy are very similar; thus, the importance of selenium in
Graves’ orbitopathy has been researched.
Treatment with selenium in the cases of orbitopathy was associated with improved
quality of life, less eye involvement, and delayed progression of eye disease at six months and 12
months when compared to treatment with pentoxifylline, a common prescription medication used
for Graves’ orbitopathy. Selenium was found to be of most benefit to patients with mild to
moderate orbitopathy. Additionally, the organic form of selenium, selenomethionine, had more
advantages in treating orbitopathy than the inorganic forms (Ventura et al., 2016). Strianese
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(2017) found that “the antioxidant effect of selenium, which may interfere with TED
progression, represents an advance in TED therapy, particularly for mild disease” (p. 511). The
findings that selenium can improve quality of life and decrease the clinical manifestations of
ocular involvement in thyroid disease will be helpful in treating the disease, since selenium has
the potential to treat not only the thyroid but also Graves’ orbitopathy.
Winther et al.’s (2017) study found that selenium supplementation improved quality of
life and ophthalmological status after only 6 months of treatment, concluding that treatment with
selenium for 6 months improves Graves’ orbitopathy. The study also discovered an association
between selenium deficiency and the development of orbitopathy, hypothesizing selenium
deficiency may be an independent risk factor for Graves’ orbitopathy (Winther et al., 2017).
Additionally, Marino et al. (2018) found that 12 months after withdrawal of selenium treatment,
patients still had improved ocular status, indicating a persistence of benefits of selenium
supplementation. Due to the unvarying findings of the benefits of selenium in Graves’
orbitopathy and the lasting benefits of supplementation, it has been recommended that patients
with mild ocular involvement start selenium supplementation for 6 months, especially patients
that are selenium deficient (Marino et al., 2018).

Key Points
•

Graves’ hyperthyroidism is a common autoimmune disease that accrues damage
from oxidative stress and ROS affecting an estimated 10 million Americans each
year.
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Selenium, which is highly concentrated in the thyroid gland, is an antioxidant that
helps decrease oxidative stress and ROS involvement in the body; and, may be
clinical useful in reducing the autoimmune response that occurs in Graves’
hyperthyroidism.

•

Selenium, in addition to methimazole, has been shown to help a patient attain an
euthyroid state faster and maintaining the euthyroid state better than just
methimazole alone.
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